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Severe plasmodium vivax infections in children
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Background: Severe clinical cases exclusively associated with
Plasmodium vivax are increasingly being reported worldwide with
complications like renal failure, jaundice, acute respiratory distress
syndrome, cerebral malaria, seizures, anemia, thrombocytopenia,
pulmonary edema, splenic rupture anddeath. Recently vivax sever-
ity has been on the rise in India where P.vivax contributes in
equal ratio with P.falciparum to the disease. Two main transporters
studied with regard to chloroquine resistance (CQR) are chloro-
quine resistance transporter (pvcrt-o) and themultidrug resistance
transporter (pvmdr1) orthologous to the pfcrt and pfmdr1 genes
respectively. Even though these transporters are not established
as molecular markers for CQR, they have a speculated role in CQR
of P.vivax. Further, it has been demonstrated that the clinical sever-
ity in P.vivax could be associated with increased expression levels
of pvcrt-o and pvmdr1 genes.
We report here two cases of vivax malaria- a severe and
non-severe case, diagnosed and conﬁrmed by microscopy, rapid
diagnostic tests and 18S rRNA PCR assay.
Methods & Materials: Relative quantiﬁcation was carried out
to ﬁnd the expression levels of ﬁve vir genes (vir 14-related, vir
12, vir 17-like, putative vir 14 and vir 10-related) and two P. vivax
speculateddrug resistancegenesviz.P. vivax chloroquine resistance
transporter (pvcrt-o) gene and P. vivax multidrug resistance trans-
porter (pvmdr1) gene. These genes were selected on the basis of
their in silico data and a previous understanding of their speculated
role in the pathogenesis of P. vivax.
Results: Expression pvcrt-o and pvmdr1 genes and ﬁve vir genes
(vir 14-related, vir 12, vir 17-like, putative vir 14 and vir 10-related),
were measured simultaneously in these two cases for comparison.
It was found that the expression levels of pvcrt-o and pvmdr1 genes
and vir genes (vir 14-related, vir 12, vir 17-like and vir 10-related),
was much higher in the severe vivax isolate as compared to the
uncomplicated case. Putative vir14 gene was not expressed in the
test and control isolates.
Conclusion: It brings to light how genes linked to the emerging
CQR inP.vivaxmight impartvirulence tovivaxmalariamaking them
excellent genetic markers for disease severity.
http://dx.doi.org/10.1016/j.ijid.2016.02.443
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Background: Mistrust, suspicion and rumours have circulated
around the purpose and motives behind recent Ebola vaccine clin-
ical trials. EBOVAC-Salone is a community-based Phase II trial of
the candidate Ad26.ZEBOV/MVA-BN-Filo prime-boost vaccine reg-
imen against Ebola being conducted in Kambia, Sierra Leone. In
this setting, we established a system for regular dialogue between
trial staff and community members in order to build and sustain
trust and to provide a mechanism to listen and respond promptly
to rumours, concerns or misinformation in the community.
Methods & Materials: A local community liaison team
engage with the community at levels. Strategies include one-to-
one engagement with key stakeholders; public meetings with
inﬂuential civil society and traditional leaders; house-to-house
sensitisation, and use of traditional communication media such as
radio.
In addition, a social science team act as the ‘eyes and ears’
for the trial, listening to what individuals are saying about the
study through both informal community observation and formal
clinic exit interviews, in-depth interviews with participants and
key stakeholders, and focus group discussions. The social science
team provide daily feedback to the community liaison team on any
rumours, concerns or misinformation circulating in the commu-
nity, to inform prompt responses or clariﬁcations. Furthermore,
an external communications manager monitors national-level
rumours and concerns and provides information on the trial at
national and international level.
Results: Full engagement has occurred with both local leaders
and the community. Enrolment in the trial has occurred suc-
cessfully thus far, with trial participants voluntarily acting as
ambassadors and encouraging others to volunteer. No disruption
has occurred to the trial through rumours or misinformation thus
far. Inﬂuential individuals in the community have assisted with
disseminatingmessages and promptly addressingmisconceptions.
Conclusion: Through a novel collaboration, we have formed an
effective rapid response system for rumours and misinformation
related to an Ebola vaccine trial during an outbreak. In addition, we
have developed strong collaboration with the community through
regular dialogue with stakeholders and trial participants. As a
result, a community in rural Sierra Leone with no previous experi-
ence of medical research have developed a strong acceptance and
understanding of the purpose of and processes involved in an Ebola
vaccine trial.
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